Kemp Dolliver
Stock Analyst at Brookline Capital
(0.60)
# 4,127
Out of 5,182 analysts
19
Total ratings
38.46%
Success rate
-17.01%
Average return
Main Sectors:
Stocks Rated by Kemp Dolliver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LSTA Lisata Therapeutics | Downgrades: Hold | n/a | $3.18 | - | 2 | Jan 21, 2026 | |
| RNTX Rein Therapeutics | Downgrades: Hold | n/a | $1.45 | - | 2 | Jan 21, 2026 | |
| VRCA Verrica Pharmaceuticals | Upgrades: Buy | $17 | $6.53 | +160.34% | 3 | Dec 18, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $18 | $4.38 | +310.96% | 1 | Jul 21, 2025 | |
| IBIO iBio, Inc. | Initiates: Buy | $3.6 | $1.63 | +120.86% | 1 | Jul 22, 2024 | |
| DARE Daré Bioscience | Upgrades: Buy | $36 | $2.19 | +1,543.84% | 2 | May 15, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $31 | $0.26 | +11,880.16% | 1 | Jan 25, 2024 | |
| LNTH Lantheus Holdings | Initiates: Buy | $100 | $83.55 | +19.69% | 1 | Nov 30, 2023 | |
| EDSA Edesa Biotech | Maintains: Buy | $57 | $14.26 | +299.72% | 2 | Oct 12, 2023 | |
| GNLX Genelux | Initiates: Hold | $25 | $2.52 | +892.06% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $6.15 | +204.88% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $8 | $0.99 | +711.52% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5.65 | $0.27 | +1,965.06% | 1 | Feb 2, 2022 |
Lisata Therapeutics
Jan 21, 2026
Downgrades: Hold
Price Target: n/a
Current: $3.18
Upside: -
Rein Therapeutics
Jan 21, 2026
Downgrades: Hold
Price Target: n/a
Current: $1.45
Upside: -
Verrica Pharmaceuticals
Dec 18, 2025
Upgrades: Buy
Price Target: $17
Current: $6.53
Upside: +160.34%
Radiopharm Theranostics
Jul 21, 2025
Initiates: Buy
Price Target: $18
Current: $4.38
Upside: +310.96%
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $1.63
Upside: +120.86%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $2.19
Upside: +1,543.84%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $0.26
Upside: +11,880.16%
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $83.55
Upside: +19.69%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $14.26
Upside: +299.72%
Genelux
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $2.52
Upside: +892.06%
Jan 13, 2023
Initiates: Buy
Price Target: $19
Current: $6.15
Upside: +204.88%
Oct 21, 2022
Assumes: Buy
Price Target: $8
Current: $0.99
Upside: +711.52%
Feb 2, 2022
Initiates: Buy
Price Target: $5.65
Current: $0.27
Upside: +1,965.06%